A recent randomized, double-blind clinical trial found that lisdexamfetamine dimesylate, approved to treat attention-deficit/hyperactivity disorder (ADHD), was effective in decreasing binge-eating days relative to placebo in patients with binge-eating disorder (BED) (McElroy S et al. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2014.2162 [published online January 14, 2015]).
The study included 259 and 255 adults with BED in safety and intention-to-treat analyses, respectively. Participants were randomly assigned to receive lisdexamfetamine in dosages of 30, 50, or 70 mg/day or placebo (1:1:1:1) for 11 weeks. Compared with placebo, binge-eating days per week decreased significantly in the 50-mg/day and 70-mg/day treatment groups but not in the 30-mg/day treatment group. The percentage of patients who achieved binge-eating cessation for 4 weeks was lower in the placebo group (21.3%) compared with the 50-mg/day (42.2%) and 70-mg/day (50%) treatment groups based on self-reported diaries and clinician interviews.
Slomski A. ADHD Drug Decreased Binge Eating. JAMA. 2015;313(12):1200. doi:10.1001/jama.2015.2209
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: